Diagnosis and treatment of cutaneous leishmaniasis

Expert Review of Dermatology

Volumn 3, Issue 3, 2008, Pages 315-327

  Reithinger, Richard ^a,b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Cutaneous leishmaniases; Diagnosis; Disease prevention and control; Epizoology; Neglected disease; Treatment

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; DAPSONE; FLUCONAZOLE; IMIQUIMOD; INSECT REPELLENT; INSECTICIDE; ITRACONAZOLE; KETOCONAZOLE; MEFLOQUINE; MEGLUMINE ANTIMONATE; MICONAZOLE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PENTAMIDINE ISETHIONATE; STIBOGLUCONATE SODIUM;

AFRICA; ASIA; BED NET; CLINICAL FEATURE; CLINICAL PRACTICE; CONFLICT; DRUG COST; ENDEMIC DISEASE; ENZYME ELECTROPHORESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GIEMSA STAIN; HEART DISEASE; HUMAN; HYPERTHERMIC THERAPY; HYPOGLYCEMIA; HYPOTENSION; INFECTION PREVENTION; INSECT CONTROL; KIDNEY FAILURE; LEISHMANIA; LEISHMANIA BRAZILIENSIS; LEISHMANIA PANAMENSIS; LEISHMANIN SKIN TEST; LIVER DYSFUNCTION; MIDDLE EAST; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; PARASITE IDENTIFICATION; PARASITE TRANSMISSION; PATHOGENESIS; PATIENT COMPLIANCE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSYCHODIDAE; RECOMMENDED DRUG DOSE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SKIN BIOPSY; SKIN LEISHMANIASIS; SKIN NODULE; SKIN ULCER; SOUTH AND CENTRAL AMERICA; TERATOGENICITY; TISSUE INJURY; TOURISM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WOUND HEALING;

EID: 55249086987     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.3.3.315     Document Type: Review

References (98)

1. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect. Dis. 5, 763-774(2005).
2. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 366, 1561-1577 (2006).
3. Chappuis F, Sundar S, Hailu A et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat. Rev. Microbiol. 5, 873-882 (2007).
4. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect. Dis. 7, 581-596 (2007).
5. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kalaazar dermal leishmantasis. Lancet Infect. Dis. 3, 87-98 (2003).
6. Puig L, Pradinaud R. Leishmania and HIV coinfection: dermatological manifestations. Ann. Trop. Med. Parasitol. 97(Suppl. 1), S107-S114 (2002)
7. Desjeux P. Leishmaniasis. Nat. Rev. Microbiol. 2, 692 (2004).
8. Molina R, Gradoni L, Alvar J. HIV and the transmission of Leishmania. Ann. Trop. Med. Parasitol. 97(Suppl. 1), 29-45 (2003).
9. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin. Microbiol. Rev. 19, 111-126 (2006).
10. Blum J, Desjeux P, Schwartz E, Beck B, Harz C. Treatment of cutaneous leishmaniasis among travellers. J. Antimicrob. Chemother. 53, 158-166 (2004).
11. Lawn SD, Whetham J, Chiodini PL et al. New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers. QJM 97, 781-788 (2004).
12. Antinori S, Gianelli E, Calattini S, Longhi E, Gramiccia M, Corbellino M. Cutaneous leishmaniasis: an increasing threat for travellers. Clin. Microbiol Infect. 11, 343-346 (2005).
13. Weina PJ, Neafie RC, Wortmann G, Polhemus M, Aronson NE. Old world leishmaniasis: an emerging infection among deployed US military and civilian workers. Clin. Infect. Dis. 39, 1674-1680 (2004).
14. CDC. Update: cutaneous Ieishmaniasis in U.S. military personnel - Southwest/Central Asia, 2002-2004. MMWR Morb. Mortal, Wkly Rep. 53, 264-265 (2004).
15. Herwaldt BL. Laboratory-acquired parasitic infections from accidental exposures. Clin. Microbiol. Rev. 14, 659-688 (2001).
16. Killick-Kendrick R. The biology and control of phlebotominc sandflies. Clin. Dermatol. 17, 279-289 (1999).
17. Handman E, Elso C, Foote S. Genes and susceptibility to leishmaniasis. Adv. Parasitol. 59, 1-75 (2005).
18. Weigel MM, Armijos RX, Zurita. C, Racincs J, Reddy A. Mosquera J. Nutritional status and cutaneous leishmaniasis in rural Ecuadorian children. J. Trop. Pediatr. 41, 22-28 (1995).
19. Yadon ZE, Rodrigues LC, Davies CR, Quigley MA. Indoor and peridomestic transmission of American cutaneous leishmaniasis in northwestern Argentina: a retrospective case-control study. Am. J. Trop. Med. Hyg. 68, 519-526 (2003).
20. Alexander B, Maroli M. Control of phlebotomine sandflies. Med. Vet. Entomol. 17, 1-18 (2003).
21. Peters W, Killick-Kendrick R. The leishmaniases in biology and medicine. In: Clinical Aspects and Control (volume 2). Academic Press, London, UK (1987).
22. Turetz ML, Machado PR, Ko AI et al. Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. J. Infect. Dis. 186, 1829-1834 (2002).
23. Barral A, Guerreiro J, Bomfim G, Correia D, Barral-Netto M, Carvalho EM. Lymphadenopathy as the first sign of human cutaneous infection by Leishmania bradziliensis. Am. J. Trop. Med. Hyg. 53, 256-259 (1995).
24. Reithinger R, Aadil K, Kolaczinski J, Mohsen M, Hami S. Social impact of leishmaniasis, Afghanistan. Emerging Infect. Dis. 11, 634-636 (2005).
25. Kharfi M, Fazaa B, Chaker E, Kamoun MR. Mucosal localization of leishmaniasis in Tunisia: 5 cases. Ann. Dermatol. Venereol. 130, 27-30 (2003).
26. Morsy TA, Khalil NM, Salama MM, Hamdi KN, Shamrany YA, Abdalla KF. Mucosal leishmaniasis caused by Leishmania tropica in Saudi Arabia. J. Egypt Soc. Pantsitol. 25, 73-79 (1995).
27. Aliaga L, Cobo F, Mediavilla JD et al. Localized mucosal leishmaniasis due to Leishmania (Leishmania) infantum: clinical and microbiologic findings in 31 patients. Medicine (Balt.) 82, 147-158 (2003).
28. Marsden PD. Mucosal leishmaniasis ('espundia' Escomel, 1911). Trans. R. Soc. Trop. Med. Hyg. 80, 859-876 (1986).
29. Boaventura VS, Cafe V, Costa J et al. Concomitant early mucosal and cutaneous leishmaniasis in Brazil. Am. J. Trop. Med. Hyg. 75, 267-269 (2006).
30. Walton BC, Chinel LV, Eguia OE. Onset of Espundia after many years of occult infection with Leishmania braziliensis. Am. J. Trop. Med. Hyg. 22, 696-698 (1973)
31. David C, Dimier-Divid L, Vargas F, Torrez M, Dedet JP. Fifteen years of cutaneous and mucocutancous leishmaniasis in Bolivia: a retrospective study. Trans. R. Soc. Trop. Med Hyg. 87, 7-9 (1993).
32. Escobar MA, Mertinez F, Scott Smith D, Palma GI. American cutaneous and mucocutaneous leishmaniasis (regumentary): a diagnostic challenge. Trop; Doct. 22, 69-78 (1992).
33. Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J. Clin. Microbiol. 45, 21-25 (2007).
34. Garcia L, Kindt A, Bermudez H et al. Culture-independent species typing of neotropical Leishmania for clinical validation of a PCR-based assay targeting heat shock protein 70 genes. J. Clin. Microbiol. 42, 2294-2297 (2004).
35. De Doncker S, Hutse V, Abddelati S et al. A new PCR-ELISA for diagnosis of visceral leishmaniasis in blood of HIV-negative subjects. Trans. R. Soc. Trop. Med. Hyg. 99, 25-31 (2005).
36. Espy MJ, Uhl JR, Sloan LM et al. Real-time PCR in clinical microbiology: applications for routine laboratory testing. Clin. Microbiol. Rev. 19, 165-256 (2006).
37. Mary C, Faraut F, Lascombe L, Dumon H. Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity. J. Clin. Microbiol. 42, 5249-5255 (2004).
38. van der Meide WF, Schoone GJ, Faber WR et al. Quantitative nucleic acid sequence-based assay as a new molecular tool for detection and quantification of Leishmania parasites in skin biopsy samples. J. Clin. Microbiol. 43, 5560-5566 (2005).
39. Garcia AL, Kindt A. Quispe-Tintaya KW et al. American tegumentary leishmaniasis: antigen-gene polymorphism, taxonomy and clinical pleomorphism. Infect. Genet. Evol. 5, 109-116 (2005).
40. Schubach A, Haddad F, Oliveira-Neto MP et al. Detection of Leishmania DNA by polymerase chain reaction in scars of treated human patients. J. Infect. Dis. 178, 911-914 (1998).
41. Vergel C, Palacios R, Cadena H et al. Evidence for Leishmania (Viannia) parasites in the skin and blood of patients before and after treatment. J. Infect. Dis. 194, 503-511 (2006).
42. van der Meide W, Guerra J, Schoone G et al. Comparison between quantitative nucleic acid sequence-based amplification, real-time reverse transcriptase PCR, and real-time PCR for quantification of Leishmania parasites. J. Clin. Microbiol. 46, 73-78 (2008).
43. Ramirez JR, Agudelo S, Muskus C et al. Diagnosis of cutaneous leishmaniasis in Colombia: the sampling site within lesions influences the sensitivity of parasitologic diagnosis. J. Clin. Microbiol. 38, 3768-3773 (2000).
44. Weigle KA, Iabrada LA, Lozano C, Santrich C, Backer DC. PCR-Based diagnosis of acute and chronic cutaneous leishmaniasis caused by Leishmania (Viannia). J. Clin. Microbiol. 40, 601-606 (2002).
45. Strauss-Ayali D, Jaffe CL, Burshtain O, Gonen L, Baneth G. Polymerase chain reaction using noninvasively obtained samples, for the detection of Leishmania infantum DNA in dogs. J. Infect. Dis. 189, 1729-1733 (2004).
46. Matsumoto T, Hashiguchi Y, Gomez EA et al. Comparison of PCR results using scrape/exudate, syringc-sucked fluid and biopsy samples for diagnosis of cutaneous leishmaniasis in Ecuador. Trans. R. Soc. Trop. Med. Hyg. 93, 606-607 (1999).
47. Bensoussan E, Nasereddin A, Jonas F, Schnur LF, Jaffe CL. Comparison of PCR assays for diagnosis of cutaneous leishmaniasis. J. Clin. Microbiol. 44, 1435-1439 (2006).
48. Chappuis F, Rijal S, Soto A. Menten J, Boelaert M. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. Br. Med. J. 333, 723 (2006).
49. Kar K. Serodiagnosis of leishmaniasis. Crit. Rev. Microbiol. 21, 123-152 (1995).
50. Montoya Y, Leon C, Talledo M et al. Recombinant antigens for specific and sensitive serodiagnosis of Latin American tegumentary leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 91, 674-676 (1997).
51. Vexenat Ade C, Santana JM, Teixeira AR. Cross-reactivity of antibodies in human infections by the kinetoplastid protozoa Trypanosoma cruzi, Leishmania chagasi and Leishmania (Viannia) brazillensis. Rev. Inst. Med. Trop. Sao Paulo 38, 177-185 (1996).
52. Weigle KA, de Davalos M, Heredia P, Molineros R, Saravia NG, D'Alcssandro A. Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: a comparison of seven methods. Am. J. Trop. Med. Hyg. 36, 489-496 (1987).
53. Weigle KA, Valderrama L, Arias AL, Santrich C, Saravia NG. Leishmanin skin test standardization and evaluation of safety, dose, storage, longevity of reaction and sensitization. Am. J. Trop. Med. Hyg. 44, 260-271 (1991).
54. Fagundes A, Marzochi MC, Perez M et al. Skin reactivity to thimerosal and phenol-preserved Montenegro antigen in Brazil. Acta Trop. 101, 25-30 (2007).
55. Convit J. Leishmaniasis: immunological and clinical aspects and vaccines in Venezuela. Clin. Dermatol. 14, 479-487 (1996).
56. Roussel M, Nacher M, Fremont G et al. Comparison between one and two injections of pentamidine isethionate, at 7 mg/kg in each injection, in the treatment of cutaneous leishmaniasis in French Guiana. Ann. Trop. Med. Parasitol. 100, 307-314 (2006).
57. Lai A, Fat EJ, Vrede MA, Soetosenojo RM, Lai A, Fat RF. Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam. Int. J. Dermatol. 41, 796-800 (2002).
58. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin. Infect. Dis. 24, 684-703 (1997).
59. Croft SL, Yardley V. Chemotherapy of leishmaniasis. Curr. Pharm. Des. 8, 319-342 (2002).
60. Franke ED, Wignall FS, Cruz ME et al. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann. Intern. Med. 113, 934-940 (1990).
61. Amato VS, Tuon FF, Siqueira AM, Nicodemo AC, Neto VA. Treatment of mucosal leishmaniasis in Latin America: systematic review. Am. J. Trop. Med. Hyg. 77, 266-274 (2007).
62. Reithinger R, Mohsen M, Wahid M et al. Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial. Clin. Infect. Dis. 40, 1148-1155 (2005).
63. Arana BA, Mendoza CE, Rizzo NR, Kroeger A. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am. J. Trop. Med. Hyg. 65, 466-470 (2001).
64. Palacios R, Osorio LE, Grajalew LF, Ochoa MT. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania Viannia species. Am. J. Trop. Med. Hyg. 64, 187-193 (2001).
65. Arana BA, Navin TR, Arana FE, Berman JD, Rosenkaimer F. Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-γ in treating cutaneous leishmaniasis in Guatemala. Clin. Infect. Dis. 18, 381-384 (1994).
66. Wortmann G, Miller RS, Oster C, Jackson J, Aronson N. A randomized, double-blind study of the efficacy of a 10-or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States military personnel. Clin. Infect. Dis. 35, 261-267 (2002).
67. Franke ED, Llanos-Cuentas A, Echevarria J et al. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis. Am. J. Trop. Med. Hyg. 51, 77-82 (1994).
68. Yardley V, Croft SL. A comparison of the activities of three amphotericin B lipid formulations against experimental visceral and cutaneous leishmaniasis. Int. J. Antimicrob. Agents 13, 243-248 (2000).
69. Soto-Mancipe J, Grogi M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin. Infect. Dis.16, 417-425 (1993).
70. Andersen EM, Cruz-Saldarriaga M, Llanos-Cuentas A et al. Comparison of meglumine antimoniate and pentamidine for Peruvian cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 72, 133-137 (2005).
71. Soto J, Buffet P, Grogl M, Berman J. Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine. Am. J. Trop. Med. Hyg. 50, 107-111 (1994).
72. de Paula CD, Sampaio JH, Cardoso DR. Sampaio RN. [A comparative study between the efficacy of pentamidine isothionate given in three doses for one week and N-methil-glucamine in a dose of 20 mg SbV/day for 20 days to treat cutaneous leishmaniasis]. Rev. Soc. Bras. Med. Trop. 36, 365-371 (2003).
73. Nacher M, Carme B, Sainte Marie D et al. Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana. Ann. Trop. Med. Parasitol. 95, 331-336 (2001).
74. Correia D, Macêdo VO, Carvalho EM et al. [Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis]. Rev. Soc. Bras. Med. Trop. 29, 447-453 (1996).
75. Soto J, Grogl M, Berman J, Olliaro P. Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 88, 695-698 (1994).
76. Hepburn NC, Tidman MJ, Hunter JA. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 88, 700-703 (1994).
77. Teklemariam S, Hiwot AG, Frommel D, Miko TL, Ganlov G, Bryceson A. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica. Trans. R. Soc. Trop. Med. Hyg. 88, 334-339 (1994).
78. Romero GA, Lessa HA, Orge MG, Macêdo VO, Marsden PD. [Treatment of mucosal leishmaniasis with aminosidine sulfate: results of two year follow-up]. Rev. Soc. Bras. Med. Trop. 31, 511-516 (1998).
79. Soto J, Hernandez N, Mejia H, Grogl M, Berman J. Successful treatment of New World cutaneous leishmaniasis with a combination of topical paromomycin/methylbenzethonium chloride and injectable meglumine antimonate. Clin. Infect. Dis. 20, 47-51 (1995).
80. Soto J, Fuya P, Herrera R, Berman J. Topical paromomycin/ methylbenzedionium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin. Infect. Dis. 26, 56-58 (1998).
81. Arevalo I, Ward B, Miller R et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin. Infect. Dis. 33, 1847-1851 (2001).
82. Miranda-Verástegui C, Llanos-Cuentas A, Arévalo I, Ward BJ, Matlashewski G. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin. Infect. Dis. 40, 1395-1403 (2005).
83. Arevalo I, Tulliano G, Quispe A et al. Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis. Clin. Infect. Dis. 44, 1549-1554 (2007).
84. Firooz A, Khamesipour A, Ghoorchi MH et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch. Dermatol. 142, 1575-1579 (2006).
85. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N. Engl. J. Med. 346, 891-895 (2002).
86. Navin TR, Arana BA, Arana FE, Berman JD, Chajon. JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J. Infect. Dis. 165, 528-534 (1992).
87. Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 89, 147-155 (1990).
88. Soto J, Toledo J, Gutierrez P et al. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. 33, E57-E61 (2001).
89. Soto J, Arana BA, Toledo J et al. Miltefosine for New World cutaneous leishmaniasis. Clin. Infect. Dis. 38, 1266-1272 (2004).
90. Soto J, Rea J, Balderrama M, Toledo J, Soto P, Berman J. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 78(2), 210-211 (2008).
91. Soto J, Toledo J, Valda L et al. Treatment of Bolivian mucosal leishmaniasis with miltefosine. Clin. Infect. Dis. 44, 350-356 (2007).
92. Navin TR, Arana BA, Arana FE, de Merida AM, Castillo AL, Pozuelos JL. Placebo-controlled clinical trial of meglumine antimonate (Glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala. Am. J. Trop. Med. Hyg. 42, 43-50 (1990).
93. Velasco-Castrejon O, Walton BC, Rivas-Sanchez B et al. Treatment of cutaneous leishmaniasis with localized current field (radio frequency) in Tabasco, Mexico. Am. J. Trop. Med. Hyg. 57, 309-312 (1997).
94. Bailey MS, Green AD, Ellis CJ et al. Clinical guidelines for the management of cutaneous leishmaniasis in British military-personnel. J. R. Army Med. Corps 151, 73-80 (2005).
95. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am. J. Trop. Med. Hyg. 46, 296-306 (1992).
96. Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol. 22, 552-557 (2006).
97. Goodwin LG. Pentostam (sodium stibogluconate); a 50-year personal reminiscence. Trans. R. Soc. Trop. Med. Hyg. 89, 339-341 (1995).
98. Modabber F, Buffet PA, Torreele E, Milon G, Croft SL. Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006. Kinetoplastid Biol. Dis. 6, 3 (2007).